Yale University

The practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?

TitleThe practice of office-based buprenorphine treatment of opioid dependence: is it associated with new patients entering into treatment?
Publication TypeJournal Article
Year of Publication2005
AuthorsSullivan, Lynn E., Marek Chawarski, Patrick G. O'Connor, Richard S. Schottenfeld, and David A. Fiellin
JournalDrug and alcohol dependence
Volume79
Issue1
Pagination113-6
Date Published2005 Jul
ISSN0376-8716
KeywordsAdolescent, Adult, Aged, Buprenorphine, Cross-Sectional Studies, Female, Humans, Male, Mental Health Services, Middle Aged, Narcotic Antagonists, Office Visits, Opioid-Related Disorders, Physician's Practice Patterns
AbstractOffice-based buprenorphine holds the promise of bringing patients who have never received pharmacotherapy into treatment. In a cross-sectional and longitudinal analysis, we compared patients entering a clinical trial of buprenorphine in a Primary Care Clinic (PCC) and those entering a local Opioid Treatment Program (OTP) and we compared the clinical characteristics and treatment outcomes of PCC patients with no history of methadone treatment (new-to-treatment) to those with prior methadone treatment. PCC subjects (N=96) were enrolled in a 26-week randomized clinical trial of office-based buprenorphine/naloxone provided in a PCC. OTP subjects (N=94) were enrolled in methadone maintenance during the same time period. PCC subjects compared with OTP subjects were more likely to be male (77% versus 55%, p<0.01), full-time employed (46% versus 15%, p<0.001), have no history of methadone treatment (46% versus 61%, p<0.05), have fewer years of opioid dependence (10 versus 15, p<0.001), and lower rates of injection drug use (IDU) (44% versus 60%, p=0.03). The new-to-treatment PCC subjects were younger (36 years versus 41 years, p=0.001), more likely to be white (77% versus 57%, p=0.04), had fewer years of opioid dependence (7 versus 14, p<0.001), were less likely to have a history of IDU (35% versus 54%, p=0.07), and had lower rates of hepatitis C (25% versus 61%, p=0.002) than subjects with prior methadone treatment. Abstinence and treatment retention were comparable in both groups. The results suggest that office-based treatment of opioid dependence is associated with new types of patients entering into treatment. Treatment outcomes with buprenorphine in a PCC do not vary based on history of prior methadone treatment.
DOI10.1111/j.1475-6773.2011.01335.x
Alternate JournalDrug Alcohol Depend

External Links